NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 445 taking part
- Started
- 27 Aug 2021
- Primary completion
- 30 Dec 2025
- Arms
- AK104+chemotherapy± bevacizumab
- Results
- None posted
- 29 Jul 2021: Trial registered
- 27 Aug 2021: Trial started